Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target

Morgan Stanley analyst Jeffrey Hung upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Equal-Weight and announces $9 price target.

Morgan Stanley analyst Jeffrey Hung upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Equal-Weight and announces $9 price target.

Total
0
Shares
Related Posts